Publication
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Authors not recorded
J Clin Oncol2010PMID 20368568PMC2881718stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerThyroid Gland Medullary Carcinomacivic_curation1.00
- drugSorafenibcivic_curation1.00
- geneRETcivic_curation1.00
- variantRET M918Tcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20368568
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RET M918T1 | ||||||||
| Sorafenib | Thyroid Gland Medullary CarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1365In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET muta… (full text at CIViC) PMID 20368568 · Lam et al., 2010 · Open in CIViC | civic |